Abstract

Ultra-low-dose nivolumab significantly improves OS versus chemotherapy in pretreated solid tumors, with fewer severe toxicities and better QoL. These findings support re-evaluation of ICI dosing strategies and may enhance global access.

Key Points

• Overall survival is significantly improved with ultra-low-dose nivolumab compared to chemotherapy, indicating its potential as an effective treatment.
• Severe toxicities are fewer with ultra-low doses, leading to better quality of life for patients undergoing treatment.
• Phase III superiority randomized trial design strengthens the validity of findings and supports new insights into immunotherapy administration.
• The results imply a need to re-evaluate dosing strategies to improve global access to effective cancer treatments.